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AIM  
 
 To observe the change in serum bone biomarkers over a period of six months    
 
among patients with acute spinal cord injury.  
 
 
 
 
OBJECTIVES 
 Compare the bone biomarker levels of acute spinal cord injury patients with 
age matched control group of premenopausal female and vulnerable group of 
post menopausal female in the community. 
 
 To observe the effect of Vitamin D on the bone biomarkers. 
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INTRODUCTION 
 
Spinal cord injury (SCI) is a partial or total disruption of the structural or functional 
integrity of the spinal cord following non-traumatic or traumatic cause leading to 
temporary or permanent impairment of motor, sensory and/or autonomic functions.  
The spinal cord transmits and modulates the neural signals between the brain and the 
target organs in the body, also contains neural circuits that can independently control 
numerous reflexes. The disruption of these neurohumoral functions following spinal 
cord injury results in various acute and chronic secondary complications including 
osteoporosis. Sublesional skeletal tissue, i.e. below the neurological level, undergo 
significant metabolic changes due to mechanical unloading, loss of neurogenic control 
over blood vessels and hormonal changes following spinal cord injury.(1) The 
changes in bone metabolism have been shown to start within weeks of injury, in the 
form of bone loss which manifest  later as osteoporosis, a state of reduced bone 
strength .(2) Osteoporosis seems to be an inevitable sequel in all complete spinal cord 
injury patients, which predisposes them to low trauma fractures. Often the diagnosis 
of osteoporosis is delayed in SCI patients and treated when present with pathological 
fractures. In view of the high morbidity and medical expenses following pathological 
fractures, there has been paradigm shift in management of osteoporosis. Currently the 
focus is to prevent bone loss in the acute phase and treat established low bone mass of 
chronic spinal cord injury.(3)(4) Literature reports that about 25% of bone loss takes 
place within first twelve months of spinal cord injury and thereafter it plateaus within 
next few years.(5)(6) Thus prevention of excess bone loss in the acute phase will 
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prevent osteoporosis and reduce chances of fracture. Bone biomarkers are the newer 
modalities which inform us about the metabolic changes related to remodelling in 
bone.(7) These are chosen over DEXA scan as they give us an idea about the dynamic 
changes in the bone over a period of time and throw light on the pathology of bone 
loss. This study observed the change in percentage of the bone biomarkers with 
respect to normal range and over a period of six months post spinal cord injury, which 
helped in understanding the nature and extent of bone loss in paraplegics during the 
acute phase of injury. 
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JUSTIFICATION OF THE STUDY 
 
Incidence of sublesional fractures is high in Spinal cord injury patients. Recent 
prospective longitudinal study suggested that about 25 % SCI patients have fractures 
and very few had received prophylactic treatment.(8) Sublesional fractures increase 
the mortality and morbidity, especially the in old veterans who are at highest risk.(4) 
Thus it becomes essential to prevent fractures which affect the rehabilitation and 
quality of life in SCI patients. Fractures can be prevented by limiting bone loss during 
the acute phase. Osteoporosis and Osteopenia are inevitable complications following 
Spinal Cord injury.  Independence in mobility puts them at a risk of low trauma 
fracture with fragile /weak bones; hence it becomes essential to have bone strength 
sufficient for weight bearing. Literature review suggests limited use of antiresorptive 
agents even though the incidence of low trauma fracture is high. This could be 
attributed to lack of use of objective measures to suggest significant loss in acute 
phase. Only patients with established osteoporosis or history of fractures are treated. 
Natural history of osteoporosis in Spinal Cord injury reveals 25 % bone loss occurring 
within a year of spinal cord injury.(2) Hence it is essential to prevent bone loss in 
early phase, rather than treating established loss in chronic phase. Routinely done 
Dexa Scan ( 2 SD ) for osteoporosis will not be able to detect this early loss as 
changes in bone mineral density (BMD) are small over the years and reliable repeated 
BMD measurements are possible only after 1-2 years. (10) Bone biomarkers can 
detect change as early as 3-4 months, which help in better assessment  and evaluation 
of response to therapy.(11) Thus there is a need to detect early bone loss and initiate 
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therapeutic agents at the appropriate time. This study looks at the level of bone 
biomarkers serially over a period of 6 months to detect early bone loss.  The change in 
bone biomarkers to suggest significant bone loss (that is 30 % bone loss over 6 
months) and the timing of peak bone loss will throw light on the point of initiation of 
treatment and selection of pharmacological agents for prevention of bone loss in the 
acute stage. Least significant change as  assessed in previous studies has been used 
here for assessing percentage change in bone biomarkers over a period of six 
months.(12) 
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BONE AS A DYNAMIC ORGAN 
Bone is the structural framework of the body, characterized by its rigidity and 
hardness. It has highly organised living material having a hierarchical structure and 
specialized metabolic functions, including the power of repair and regeneration.(Fig 1) 
It constantly undergoes modeling (reshaping) during life to help it adapt to changing 
biomechanical forces which determine its structure. Throughout life it continues 
remodeling, i.e. removal of old micro-damaged bone which in turn is replaced with 
new and mechanically stronger micro structure to preserve the bone strength.(13) 
 
BONE STRUCTURE 
The bones are covered by membrane outside and it has two components enclosed 
inside, these are called cortical and trabecular bones. 
 
BONE MEMBRANES: PERIOSTEUM AND ENDOSTEUM 
The periosteum is a double layered protective membrane, comprising of an outer 
dense fibrous connective tissue layer and inner osteogenic layers comprising of bone 
cells. The inner layer is richly supplied by nerve fibres, blood vessels and lymphatics 
which enter the bone via nutrient foramina. Sharpeys’ fibers are the thick collagenous 
fibrous strands which tightly bind the periosteum and outer cortical surface together. 
The endosteum cover the inner surface of cortical and trabecular bone, Volkmann’s 
canal. It is in contact with the bone marrow space and contains blood vessels, 
osteoblasts, and osteoclasts. 
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CORTICAL / COMPACT BONE 
Cortical bone is dense and solid, surrounding the marrow space and composed of units 
called osteons, also called as Haversian systems. Haversian systems are cylindrical in 
shape, and form a branching network within the cortical bone. Concentric layers of 
lamellar bone form the walls of harvesian canals. 
Cortical bone has an outer periosteal surface and inner endosteal surface. The 
endosteal surface has higher remodeling activity than the periosteal surface, most 
likely due to greater biomechanical strain or greater inflammatory exposure from the 
adjacent bone marrow. Bones normally increase in diameter with aging as bone 
formation exceeds bone resorption on the periosteal surface. 
 
CANCELLOUS / TRABECULAR / SPONGY BONE 
Trabecular bone is a honeycomb like network of plates and rods interspersed in the 
bone marrow compartment. Trabecular osteons are also called packets. The plates and 
rods on an average have 50 to 400 mm of thickness. Trabecular osteons are semilunar 
in shape, about 35 mm thick, and composed of concentric lamellae. 
Cortical and trabecular bone both are normally formed in a lamellar pattern, in which 
collagen fibrils are laid down in an alternating fashion. 
Woven bone 
 Woven bone is normally produced during primary bone formation. It is characterised 
by random arrangement of cells and connective tissue, seen in early callus formation. 
It is seen in high bone turnover states such as osteitis fibrosa cystica, and other 
hyperparathyroid state. 
19 
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Lamellar bone 
 Orderly distribution of cells and proper orientation of collagen fibres is a typical 
feature of lamellar bone. Cortical and trabecular bone, both are normally formed in a 
lamellar pattern, in which collagen fibrils are laid down in alternating fashion.  
Alternating orientations of collagen fibrils gives significant strength to the lamellar 
bone, which is absent in the woven bone. Hence, lamellar bone has greater strength 
when compared to woven bone.   
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BONE MICRO STRUCTURE AND CHEMISTRY 
Bone tissue is composed of a mineral (inorganic) phase in an organic matrix mainly 
constituted by type I collagen fibril. It comprises of 50 to 70% mineral, 20 to 40% 
organic matrix, 5 to 10% water, 3% lipids. Bone mineral is structurally related to 
naturally occurring geological mineral hydroxyapatite   [Ca 10(PO4)6(OH)2], 
differing in crystalline size, perfection and content of impurities (Mg+2, Sr+2, CO3 2-
, H P O 4 2-). In human bone, mineral is composed of a poorly crystallized, Calcium-
deficient and non stoichiometric apatite. It contains major elements, like Ca2+ (40 wt 
%), PO4 3− (18 wt %), C03 2− (6–7 wt %), minor elements as Mg2+ or Na+, and 
trace elements (Sr2+, F−).  It is a reservoir of ions that can be stored or released by the 
means of remodeling to maintain phosphocalcic equilibrium.(14) 
 
 
22 
 
Mineral crystallites are nano-sized platelet-shaped (1–7 nm in thickness, 15–200 nm 
in length, and 10–80 nm in width). Their organization in bone tissue depends on the 
structural properties of organic matrix, which includes collagen  
that acts as a template for mineral deposition and the distribution of other matrix 
proteins.  D i e t ,  a g e ,  mineral turnover, cell viability, health status, and the use of 
therapeutic modalities also affect the crystal size and mineralisation. The mineral 
crystals are arranged parallel to each other, and crystallographic c-axis of the apatite is 
oriented parallel to the longitudinal axis of the collagen fibrils in a staggered 
arrangement, with the first nucleation within the gap zones of collagen fibrils (Fig. 1). 
Crystal nucleation is triggered by collagen and by non collagenous proteins, which 
also regulate several steps of mineralization.  
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The crystals are first elongated, typically in a plate-like shape, and then grow in 
thickness rather than in length.(15) Bone mineral provides mechanical rigidity and 
load-bearing strength. Organic matrix provides elasticity and flexibility. Bone crystals 
can be depicted in three compartments: Surrounding fluid; hydrated layer; and apatitic 
core, shown in figure 4. 
 
Ions in the hydrated layer are very labile and reactive, and constitute the nonapatitic 
domains (HPO42−, PO43−, CO3 2−). During mineral maturation, non apatitic 
domains exchange readily and reversibily with the apatitic domain which is associated 
with an increase in stable apatitic core. The presence of apatite enhances the tensile 
modulus and strength of collagen where as organic matrix directly acts on the 
proportions of loads transferred on mineral particles preventing mineral cracking. The 
“quality” of bone mineral can be described by its crystalline nature, maturity, and 
level of substitution. Crystallinity encompasses the size and perfection of the crystal 
lattice, i.e., the degree of order of the ions constituting the lattice and is therefore 
sensitive to the size and strain of crystals. The mineral maturity reflects the conversion 
of nonapatitic precursors into apatitic mineral.(16)  
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BONE CELLS AND PHYSIOLOGY 
At the tissue level, bone is composed of bone structural units (BSUs)—the osteons in 
cortical bone and bone packets in trabecular bone. These BSUs correspond to the net 
production of bone tissue following a remodeling cycle. The remodeling process takes 
place throughout the skeleton at anatomically distinct sites termed basic multicellular 
units (BMUs). The Basic Multi cellular Unit is a team of cells that dissolves a pit in 
the bone surface and then fills it with new bone”(17). Osteoclasts remove old bone, 
then osteoblasts synthesize new bone. Old bone is replaced by new bone in quantized 
packets. (19) 
 
OSTEOBLASTS 
Osteoblasts originate from osteoprogenitor cells. Osteoblasts synthesize new bone 
matrix on bone-forming surfaces, the osteocytes within bone matrix, and the 
protective lining cells that cover the surface of quiescent bone as shown in Figure 5. 
Active mature osteoblasts synthesize bone matrix. Osteoblasts secrete type I collagen 
and matrix proteins which contributes toward bone surface formation.(13) Upon 
completion of bone formation, it remains on the surface of bone.  
  
OSTEOCYTES  
Osteocytes are the terminally differentiated osteoblasts, positioned between lamellae 
in a concentric pattern around the central lumen of osteons. Osteocytes are connected 
with each other and the surface via multiple cilia like cellular processes. They function 
in a co-ordinated fashion with syncytial network responsible for mechanosensory  
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property, structural support, and metabolism. The primary function of the osteocyte-
osteoblast cellular syncytial network  is mechanosensation.(20) Osteocytes transduce 
stress signals, like stretching of bone into biologic activity, by means of flow of fluid 
within the canalicular channels. This in turn induces a variety of responses within 
osteocytes. Transmission of information between surface osteoblasts and osteocytes 
may be through calcium fluxes via gap junctions or ion channels. Osteocytes live for 
decades in low remodelling states, acting as mechanosensors, but undergo apoptosis 
once there is disruption of intercellular networks or gap junctions.(21) Oestrogen 
therapy and mechanical loading of bone may help prevent osteoblast and osteocyte 
apoptosis.(22) 
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OSTEOCLASTS 
 Osteoclasts are the only cells capable of bone resorption. Mononuclear precursor cells 
of the monocyte macrophage lineage give rise to activated multinucleated 
osteoclasts.(23) Osteoclasts attach to bone matrix via integrin receptors on the 
osteoclast membrane linked by bone matrix peptides. Osteoclasts bind to the bone 
matrix and becomes polarized, with the bone resorbing surface developing a ruffled 
border. The ruffled border secretes H+ ions via H-ATPase and chloride channels and 
exocytosis of lysozymes and cathepsin K which degrades collagen in the acidified 
vesicles.(24) A sealing zone around the periphery of osteoclast attachment to the 
matrix is formed which isolates the acidified resorption compartment from the 
surrounding bone surface.(25) 
 
 
FUNCTIONS OF BONE 
Bone is involved in wide variety of functions ranging from structural support to 
hematogenesis and biochemical mineral balance. 
  
Mechanical Support 
 Frame work of the body 
 Provides strength and stiffness  
 Hollow cylinder: Strong and light 
  Prevents fatigue fracture  
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Hematopoesis 
• Development of blood cells  
• Occurs in the marrow of bone 
• These regions are mainly composed of trabecular bone  
• (e.g. iliac crest, vertebral body, proximal and distal femur)  
 
 
Protection of vital structures 
• Flat bones in the head protect the brain 
• Protects heart and lungs in chest 
• Vertebrae in the spine protect the spinal cord and nerves 
 
 
Mineral Homeostasis 
• Primary store house of calcium and phosphorus 
• Trabecular bone is rapidly formed or destroyed 
• It response to shifts in calcium stasis without serious mechanical consequences 
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FACTORS REGULATING BONE ACTIVITY 
 
 Estrogen and Testosterone 
 PTH, Calcitonin, Vitamin D, Ca / Po4 
 Cytokines and Interleukins  
 Growth factors, 
 Transforming growth factor-a and b  
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ESTROGEN 
Estrogen acts on bone via multiple mediators, the exact mechanism of which is not 
known. Inhibitory effect of estrogen on osteoclast is removed in menopausal period 
which leads to prolonged survival and activity of osteoclasts, with increased 
remodeling rates. Morphological pattern of bone loss in menopausal females is located 
in trabeculae and endocortical surfaces. This can be explained by hypothesis that it 
causes skeletal tissue to have optimal sensitivity to loading. This loss of sensitivity to 
loading results in a morphologic pattern of bone loss that closely resembles disuse. 
Estrogen deficiency promotes T cell activity which increases osteoclast and reduces 
osteoblast activity. The inflammatory mediators involved in bone resorption are TNF 
and IL 1 and 6, which are down regulated by estrogens.(26)(27) 
 
PARATHYROID HORMONE 
PTH is the primary regulator of calcium homeostasis. It acts on three important sites, 
bone, intestine and kidney, which maintains strict control of serum calcium levels. 
Maintenance of free calcium concentration of the ECF is the basic function of PTH. 
With respect to the skeletal tissue, it acts on the bone surface in a catabolic manner 
leading to bone resorption. 
PTH acts on the kidney to increase calcium reabsorption and stimulate renal 
production of 1,25 (OH)2 Vitamin D to increase intestinal absorption of calcium and 
maintain the ECF concentration of calcium.(28) 
Bone remodeling - While its exact mechanism and function is unclear, the net result is 
increase in the synthesis of collagen. Parathyroid hormone (PTH) does this by 
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affecting the non collagenous protein bone mineral process to raise the free calcium 
level in the ECF from the base level. PTH acts on bone to release calcium in two 
phases; immediate effect is to mobilize calcium from skeletal stores that are readily 
available and in equilibrium with the extracellular fluid. Later, PTH stimulates release 
of calcium by activation of bone resorption. 
Osteoblasts, not the osteoclasts, express PTH receptors. PTH increases osteoclast 
activity indirectly through effects on RANKL and osteoprotegerin. (29) The net effect 
of PTH on bone varies according to the severity and chronicity of the PTH excess, 
ranging from osteopenia to osteitis fibrosa cystica. PTH when given intermittently 
promotes bone formation, but at high concentrations or when given continuously, it 
activates resorption and inhibits collagen synthesis. The positive effect of intermittent 
PTH on bone appears to be mediated through the PTH1R, in view of the equivalence 
of PTH (1-84) and PTH (1-34) in bone anabolism. It involves the induction of 
multiple target genes including IGF1, TGF-beta, RANKL, 1 alpha hydroxylase, and 
M-CSF; while sclerostin, an inhibitor of the wnt signalling pathway, is 
suppressed.(28) 
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CALCITONIN  
Calcitonin is a protein hormone secreted by parafollicular cells of thyroid. Ionized 
calcium regulates calcitonin secretion, increase in ionized calcium produces an 
increase in calcitonin secretion, which inhibits osteoclasts and therefore bone 
resorption in pharmacologic doses. However, its physiologic role is minimal in the 
32 
 
adult human skeleton. Its pharmacologic effects are transient, probably because of 
receptor down regulation. As a result, it is only transiently effective in treating 
hypercalcemia due to excessive bone resorption. 
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VITAMIN D 
 
Production, metabolism, and function 
Vitamin D is truly a prohormone not a vitamin. 7-dehydrocholesterol, in the skin after 
sunlight exposure (ultraviolet B light) is converted to vitamin D3. Vitamin D 3 is 
hydroxylated in the liver to 25-hydroxyvitamin D3 (25(OH) Vitamin D 3), and further 
hydroxylated in the renal proximal tubule to 1, 25-dihydroxyvitamin D3 (1, 25(OH) 2 
D3, Calcitriol), the principal active form. The production of 1, 25(OH)2 Vitamin D in 
the kidney is under tight control of parathyroid hormone (PTH) and inhibited by 
calcium, phosphate, and fibroblast growth factor 23 (FGF23). 1, 25(OH) 2 Vitamin D 
stimulates its own catabolism by induction of CYP24-hydroxylase, which avoids 
vitamin D toxicity. It is the first step in the catabolism of active Vitamin D 
metabolites. 
                                                                                                                                                                     
Vitamin D receptor and mineralisation 
VDR belongs to the steroid hormone nuclear receptor super family, and has been 
shown to regulate both gene transcription as well as rapid responses such as the 
opening of voltage-gated Ca 2+ channels, and stimulation of intestinal Ca 2+ 
absorption. Infusion of calcium and phosphate to vitamin-D–deficient rats induced 
growth and mineralization as effectively as vitamin D replacement.(31) Evidence 
indicates that the stimulation of intestinal calcium and phosphate absorption is the 
mechanism by which vitamin D increases bone mineralization, effects on matrix 
vesicles.(32) 
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Vitamin D-Regulated Bone Formation 
Vitamin D deficiency causes rickets due to hypocalcemia and hypophosphatemia. 
Skeletal changes in vitamin D deficiency are due to hyperparathyroidism that 
develops in the vitamin D-deficient state. PTH has its own actions on remodelling 
activity which affects the bone and cartilage. Terminal differentiation of the 
hypertrophic chondrocytes and the calcification of the matrix are significantly 
impaired in vitamin D deficiency which leads to flaring of ends of the long bones and 
the rachitic rosary pattern of costochondral junctions, typical features of rickets. 
Adequate supply of calcium and phosphate may correct the defects in terminal 
differentiation and calcification. Vitamin D metabolites, 1,25(OH)2D and 
24,25(OH)2D, are known to exert distinct roles in endochondral bone 
formation.(33)(34) 
 
Direct action on bone 
Vitamin D directly plays a role in osteoblast formation, mineral apposition rate, and 
bone density. Studies show trabecular bone with osteopenia, decreased mineral 
apposition rates and reduced alkaline phosphatase expression,  signifying reduced 
osteoblast number or activity.(33)(35) Endochondral bone formation is impaired in 
vitamin D deficiency associated with decrease alkaline phosphatase activity of the 
hypertrophic chondrocytes.1,25(OH)2D and 24,25 (OH)2D both  are required for 
endochondral bone formation and proliferation of hypertrophic chondrocytes.(33) 
Vitamin D affects endochondral bone formation on the one hand and systemic 
calcium/phosphate homeostasis via changes in FGF23 production on the other.(33) 
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Involvement of vitamin D in collagen cross-linking-Collagen cross-linking is 
considered as one of the determinants of bone quality. Vitamin D treatment increases 
interconnections and formed plate like structures. It maintained bone formation in the 
endocortical perimeter, and stimulated bone formation in the periosteal perimeter(32). 
Anti apoptotic effects of vitamin D have been believed to be mediated mainly through 
osteoblasts, but osteocytes may also be involved(32).  
 
Indirect action 
1,25(OH)2D3 is mainly responsible for uptake of calcium and phosphate from the 
intestine and aid in mineralisation of bone, rather than a direct action on bone.(33) 
Both indirect and direct effects of vitamin D on bone are essential and required; as 
deficiency in one, can be partially compensated by the other. 
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BONE FORMATION  
 
Bone cells (Osteoblast) and the bone matrix are the two most crucial elements 
involved in bone formation. Two important processes involved in normal bone 
formation are Intra membranous and Endochondral ossification.(36) 
 
Intramembranous ossification is the laying down of bone material into the 
mesenchyme, the primitive connective tissue resulting in the formation of bones. 
(Example - skull, mandible) 
Endochondral ossification is where a cartilage acts as a precursor for ossification (e.g. 
humerus, radius, tibia, femur) It is the process which occurs during fracture healing 
when treated by cast immobilization. 
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 CARTILAGE MODEL  
Each long bone present as a rod of hyaline cartilage in early foetal life replaces a rod 
of condensed mesenchyme. The cartilaginous model is surrounded by a vascular 
condensed mesenchyme or perichondrium, with its deeper layers containing 
osteoprogenitor cells. 
 
Growth of cartilage model- The cartilage model grows in length by continuous cell 
division of chondrocytes called as interstitial growth. The process of appositional 
growth occurs when the cartilage grows in thickness on the peripheral surface of 
cartilage that develops from the perichondrium. On reaching maturity, epiphyseal and 
metaphyseal ossification encroach upon the growth plate, followed by final bony 
fusion with cessation of growth. 
 
Development of the primary ossification centre-  
The primary centre of ossification lies in the middle of the shaft, which undergoes 
following events: 
 
• Formation of Periosteum – As vascularity improves, the perichondrium becomes the 
periosteum. Undifferentiated osteoprogenitor cells on the periosteum later become 
osteoblasts. 
• Formation of Bone Collar - The osteoblasts secrete osteoid against the shaft of the 
cartilage model (appositional growth). These acts as scaffold support for the new 
bone. 
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• Calcification of Matrix - Chondrocytes at the primary center of ossification undergo 
hyperplasia. Alkaline phosphatase secreted from the chondrocytes is essential for 
mineral deposition and calcification of the matrix. Following this, hypertrophic 
chondrocytes undergo apoptosis and creates cavities within the bone. 
 
• Invasion of Periosteal Bud - The hypertrophic chondrocytes secrete VDGFs 
(vascular endothelial cell growth factor) that induces the sprouting of blood vessels 
from the perichondrium. Sprouting blood vessels form the periosteal bud and invade 
the formed cavity carrying the hemopoietic cells and osteoprogenitor cells. The 
hemopoietic cells form the bone marrow. Osteoclasts, formed from macrophages, 
break down spongy bone to form the medullary cavity. 
 
• Formation of Trabeculae – Newly formed osteoblasts within the cavity secrete 
osteoid, which lays down over the calcified matrix acting as scaffold for bone 
trabecula.  
 
Development of the secondary ossification center  
At birth, a secondary ossification centre appears in each epiphysis of the long bones. 
Periosteal buds carry mesenchyme and blood vessels in which the primary ossification 
centre forms. The cartilage between the primary and secondary ossification centres is 
called the epiphyseal plate, and it forms new cartilage, which is replaced by bone, 
resulting in an increase in length of the bone. Growth continues until the cartilage in 
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the plate is replaced by bone or about 21 of year’s age. The point of union of the 
primary and secondary ossification centres is called the epiphyseal line. 
 
Formation of articular cartilage and epiphyseal plate: 
The cartilaginous extremity (where an epiphysis usually forms) grows by appositional 
and interstitial mechanisms. When the whole bone is reaching maturity, epiphyseal 
and metaphyseal ossification gradually encroaches upon this growth plate, and final 
bony fusion occurs with cessation of growth. 
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BONE MODELING AND REMODELING 
Bone undergoes radial and longitudinal growth, modelling, and remodeling during 
life. Modeling is a process by which bone adapts overall change in shape in response 
to mechanical forces it encounters during development. Bones normally widen with 
aging in response to periosteal apposition of new bone and endosteal resorption of old 
bone. During bone modeling, bone formation and resorption are not tightly coupled. 
Bone remodeling is removing and replacing packets of bone. It is the primary 
mechanism whereby bone is renewed and adapts to changes in load bearing. It is a 
useful process for decreasing skeleton size in the event of immobilization and for 
repairing the micro damage before they become clinically apparent. This is the 
process by which bone is renewed to maintain bone strength and mineral homeostasis 
is maintained.  It prevents accumulation of bone micro damage. The bone remodeling 
unit is composed of osteoclasts, osteocytes and osteoblasts that are tightly regulated to 
carry out resorption of old bone and formation of new bone. Osteocytes play an 
important role in cell signaling, regulating osteoblast and osteoclast function, and 
sensing mechanical loading.(37) The mechanisms controlling remodeling are largely 
unknown, but mechanical loading has a significant effect.  The number of active bone 
structural units created per unit time at any chosen surface locus is measured 
histomorphometrically as activation frequency and is a tissue-level measure of the rate 
of bone remodeling. The net amount of bone formed is termed bone balance. A 
negative bone balance occurs at menopause, immobilized patients and in astronauts in 
a microgravity environment.(38) Remodeling sites mostly develop in a random 
manner but are also targeted to areas that require repair.  
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TYPES OF REMODELLING 
 
 Targeted/Stochastic remodeling- Targeted remodeling is responsible for the 
repair of micro damage. It is supposed to be the most important pathogenetic 
factor for increased bone fragility in osteoporosis(26). Increase / accumulation 
of micro damages leads to structural failures (i.e. micro fractures)  
 
 Non targeted/Non Stochastic remodeling helps in maintaining the plasma 
calcium homeostasis. 
 
Clinical significance of remodeling 
It helps in assessment of bone activity over a period of time. Changes in bone 
remodeling can be identified over a relatively shorter time period (several days to 
months) before changes in BMD are detected. Change in remodeling markers, i.e. 
increased bone resorption markers correlate with fracture risk better than BMD. 
Clinical trials of antiresorptive agents have shown that reducing excess remodeling 
decreases fracture risk significantly.(39) 
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SEQUENTIAL PHASES OF REMODELING: 
QUIESCENCE 
It is a period of relative inactivity. After the tunnelling and refilling some osteoblasts 
become osteocytes, remain in bone and sense mechanical stresses on bone. Remaining 
osteoblasts become lining cells. Factors that activate the remodeling cycle are not yet 
known. 
 
ACTIVATION 
It occurs when bone experiences micro damage or mechanical stress, or randomly. A 
Bone Morphological Unit (BMU) originates and travels along the bone surface. This 
is followed by retraction of the bone lining cells (osteoblasts on surface) and digestion 
of the endosteal membrane by collagenase enzymes. This completes the first step 
towards activation. Activation of monocyte-macrophage system and  osteoclast 
precursor cells from the circulation, results in interaction of osteoclast and osteoblast 
precursors.(40) This leads to the differentiation, migration, and fusion of the 
multinucleated osteoclasts which attach to the mineralized bone surface and initiate 
resorption.  
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RESORPTION 
Newly differentiated osteoclasts are activated and begin resorption. Minerals are 
dissolved and the matrix is digested by lysosomal enzymes and hydrogen ions, 
particularly cathepsin K, which can degrade all the components of bone matrix, 
including collagen, at low pH. Osteoclastic resorption produces irregular cavities 
called Howship’s lacunae and cylindrical Haversian canals in trabecular bone and 
cortical bone respectively. It takes 2–4 weeks for resorption during each remodeling 
cycle. 
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REVERSAL 
 It is the transition from osteoclastic to osteoblastic activity. Cavities formed at the end 
of resorption contain monocytes, osteocytes released from bone matrix recruited to 
begin new bone formation. The proposed coupling signal candidates linking the end of 
resorption to beginning of formation are IGF-1,2, bone morphogenetic proteins, and 
fibroblast growth factor. 
 
FORMATION 
It is transition from osteoclastic to osteoblastic activity. Osteoclasts are replaced by 
cells of the osteoblast lineage. The growth factors are liberated from the matrix which 
act as chemotactics and stimulate their proliferation. The preosteoblasts secrete 
cement like substance upon which the new tissue is attached and express bone 
morphogenic proteins (BMP), which is responsible for differentiation. Differentiated 
osteoblasts synthesize the osteoid matrix which fills the cavity perforated areas (41). 
Some osteoblasts continue synthesising bone until they transform to quiescent lining 
cells that cover the new bone surface and connect with the osteocytes in the bone 
matrix through canalicular network. 
 
MINERALISATION  
Bone tissue is composed of a mineral portion in an organic matrix mainly constituted 
by type I collagen fibrils. The degree of mineralization of bone and the characteristics 
of the mineral deposited (apatite crystals) are major determinants of bone strength.  
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Mineralization involves not only the initial deposition of mineral in organic matrix but 
also its maturation until the upper mineral density in a given volume of matrix is 
reached. Mineralization is a multistep process during bone remodelling. (Fig.11). 
Newly formed organic matrix deposited by osteoblasts begins to mineralize 5–10 days 
after deposition by secondary nucleation, i.e., the crystals act as nucleation sites for 
the newer ones. This first step leads to a mineral content corresponding to 50–70 % of 
the maximal value.(42) After a few days, or weeks, the speed of mineralization 
decreases substantially and secondary mineralization begins. This latter process 
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corresponds to gradual increase in crystal size, number and/or perfection, occurring on 
the year-scale until the maximal (Mean degree of bone mineralisation) DMB is 
reached. Independent of bone mass and its distribution in space, the mineralization 
and the “quality” of the mineral play a crucial role in the elastic, plastic, and 
viscoelastic properties defining the mechanical behaviour of bones.                                                          
                                                                                                                                                                     
Mineral deposition happens at multiple discrete sites of the collagen fibers. This 
process, also, is regulated by the osteoclasts. After mineral maturation, once the cavity 
is full, the mineral crystals pack together, increasing the density of the new bone. The 
cycle continues and quiescent phase begins again. One cycle of remodelling  equalises 
amount of bone formation and  bone resorption.(43) 
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OSTEOPOROSIS  
“Osteoporosis is defined as a skeletal disorder characterized by compromised bone 
strength predisposing a person to an increased risk of fracture. Bone strength primarily 
reflects the integration of bone density and bone quality”(44). Clinical diagnosis of 
osteoporosis now depends on the presence of low-trauma fracture, defined as fracture 
resulting from trauma equal to, or less than, a fall from a standing height, excluding 
fractures of face, skull, or digits. 
OSTEOPOROSIS - REDUCED BONE STRENGTH 
 
 
 
 
 
 
 
 
 
Features of bone quality that contribute to skeletal fragility and risk of low-trauma 
fracture are defects in micro architecture of trabeculae, defective material properties of 
bone tissue, and incomplete repair of micro-damage. Defective repair of micro-
damage results from physiologic loading occurring in normal daily life. These features 
49 
 
are also observed in age-related bone loss, and increased bone remodeling rates 
greater than those found in normal premenopausal women(45)(46). 
BONE DENSITY 
Peak bone mass – It determines 50 to 70% of bone strength. Bone mass reaches its 
peak at about 20 years of age in males and 18 years in females. Peak Bone Mass 
determines long-term fracture risk. Paediatric population are at high risk for fractures 
as they have not attained their peak bone mass. 
 
BONE QUALITY 
Micro architecture  
It is essential for resistance to fracture. It comprises of amount, size, shape, and 
connectivity of trabecular bone and cortical bone tissue. In Osteoporosis there is a 
decrease in size and number of trabeculae. Thinner and rod like trabeculae, replacing 
the stronger plate like morphology that is seen in non osteoporotic bone(47). 
Excessive remodeling present in osteoporotics is likely to be the primary cause of 
these changes in micro architecture. 
 
Turnover  
Higher bone turnover influences bone strength by affecting mineralisation. When 
bone turnover is high, probability for a cortical or trabecular bone structural unit 
(BSU) to be resorbed before the completion of its secondary mineralization increases. 
This leads to greater proportion of younger and sub maximally mineralized bone.     
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An increased proportion of sub maximally mineralized bone matrix leads to an 
increase in the proportion of immature crystals with a low crystallinity. (46) 
 
Micro damage  
It occurs due to repeated sub maximal loading. It can transect lamellae and canaliculi 
and disrupt the communication of osteocytes. This process can trigger osteocyte 
apoptosis, which signals osteoclast precursors to differentiate into osteoclasts that 
target the microdamage for removal and repair by osteoblasts(48). Small cracks may 
coalesce, forming larger cracks, which, if left unrepaired, result in clinically apparent 
fractures. Once a trabecular surface is eliminated, subsequent formation does not 
happen at that location. Excess of weakened loci in trabeculae and an increase in 
micro damage outpaces the ability to repair. Micro damage increases with age, which 
can accumulate and result in structural failure (i.e. fractures). 
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Mineralisation    
Bone remodeling activity acts as a regulator of the degree of mineralization and of the 
distribution of mineral at the tissue level, directly impacting bone mechanical 
properties. Reduced bone turnover activity provide osteons and bone trabecular 
packets (BSU) with more time to complete their secondary mineralization before 
being resorbed in a further remodeling cycle. Therefore, a greater proportion of tissue 
is maximally mineralized not only increasing the mean tissue mineral content but also 
narrowing its distribution. Contrastingly when bone turnover is high, probability of 
BSU to be resorbed before completion of secondary mineralisation raises, this leads to 
younger optimally matured bone at tissue level. At crystal level, increased proportion 
of sub maximally mineralized bone matrix leads to an increase in the proportion of 
immature crystals with a low crystallinity i.e. suboptimal size and lattice structure, 
interface between collagen and crystal. (e.g. menopause). Decrease in remodelling rate 
leads to homogenous mineral characteristics (e.g., after antiresorptive treatment).(43) 
In rapid remodeling, bone strength may be compromised indicating that optimal bone 
strength rises from an optimal mineralization. 
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REMODELLING, BMD and FRACTURE – RISK 
Factors which compromise the bone strength and skeletal fragility: 
 (1) Defects in micro architecture of trabeculae,  
 (2) Defective material properties of bone tissue, 
 (3) Incomplete repair of micro damage and  
 (4) Excess bone remodeling rates. 
 
Remodelling appears to be the first detectable change following in skeletal tissue 
following SCI. Routinely done DEXA scan show changes few years when significant 
bone loss has occurred. Clinical studies of mechanical loading, estrogens deprivation, 
age related, disuse related bone loss and role of antiresorptive have improved the 
knowledge regarding factors affecting bone quality and mechanisms underlying them. 
Other aspects of bone quality not measurable clinically are probably more important 
for mechanical integrity of bone and resistance to fracture than the bone mineral 
density, especially for early detection of bone loss. It consists of the amount, size, 
shape, and connectivity of trabecular bone tissue as well as the amount and shape of 
cortical bone tissue. The trabeculae also became thinner and rod like in shape, 
replacing the stronger plate like morphology that is seen in non osteoporotic bone. The 
excessive remodeling present in most postmenopausal females is likely to be the 
primary cause of the changes in micro architecture, hence routine follow up of 
remodelling rates may suggest the dynamic changes in bone. (47). As bone turnover 
rates increase they affect mineralisation and later changes in BMD appear, as shown 
in figure 14. But as bone markers do not indicate the extent of established bone loss 
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both the parameters are required for appropriate management of osteoporosis. Anti 
resorptive treatment in Post Menopausal females increases the Bone Mineral Density, 
but more importantly reduces the remodelling rates. Change in BMD accounts for 
anti-fracture effect of antiresorptive agents, but facture risk reduction may not be 
related to changes in BMD. Low BMD is predictive of fracture in untreated patients 
whereas reduction of fracture risk in treated patients, has less to do with their BMD 
response to treatment.(49) 
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PATHPHYSIOLOGY OF BONE LOSS IN SCI 
 
1. LOCAL FACTORS  
 Mechanical unloading  
   Reduced mechanical signals  
 
2. DENERVATION  
 Autonomic dysregulation  
 Neuropeptide expression  
 
3. HORMONAL DYNAMICS   
 Suppression of PTH- Vitamin D axis following hypercalciuria in the acute 
phase of spinal cord injury. 
 Low vitamin D levels and low sun exposure following injury. 
 Increased cortisol levels due to stress. 
 Steroids in the course of treatment. 
 Inhibitory effect of Spinal Cord Injury on the synthesis and secretion of sex 
steroids contributes to the pathogenesis of SCI induced osteoporosis(26)(50) 
 
55 
 
 
 
Multiple factors are responsible for skeletal changes following SCI. The major factors 
are immobilisation and mechanical unloading during the acute phase. Bone loss is 
significantly higher in SCI related immobilisation than other causes of immobilisation. 
This is probably where SCI patients need better evaluation and aggressive 
management for prevention bone loss in acute phase, osteoporosis and pathological 
fractures in later stages.   
 
Mechanical loading play a significant role in maintaining the bone strength by 
mechanosensation mediated through osteocytes Mechanical loading leads to bone 
matrix deformation around the osteocytes, which creates perturbation of cell 
membrane (probably by stretching the glycocalyx present in the cell membrane) and 
bone fluid leading to shear stress, which contribute to mechanosensation and 
mechanotransduction. (37) 
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WNT THEORY OF BONE  
WNTs are glycoproteins that regulate cellular activities, such as cell fate, 
proliferation, migration, survival and gene expression. They play a major role in 
osteoblasts activation and bone formation, which inturn inhibits agents associated with 
bone resorption. Reduced WNT signaling has been associated with increased bone 
loss.(51) 
 
Wnts, glycoproteins undergo post-translational modification by addition of lipids, 
required for activation of bone formation. Wnt/ȕ-catenin pathway acts as a critical 
regulator of osteocyte function, responsible for mechanical loading of bone. Fluid 
flow-induced shear stress stimulates gap junction-mediated intercellular release of 
prostaglandins. (37) PGE2 increases intracellular cAMP and activate Protein Kinase 
A. Connexins form gap junctions also called hemichannels which provide a 
mechanism for ATP and NAD+ release and increases intracellular Ca2+ levels. 
Hence, Prostaglandin (PGE2) released through hemichannels in response to shear 
stress has an autocrine effect on osteocytes through the EP2 receptor.  (41)(26). 
Currently accepted paradigm states that Wnt binds to a co receptor complex involving 
Frizzled receptor and low density lipoprotein receptor-related protein (LRP)-5, present 
on osteoblasts. This binding stabilizes cytoplasmic ȕ-catenin and translocates it to the 
nucleus. Translocation activates transcription of genes that promote osteoblast 
proliferation and differentiation, ultimately resulting in new bone formation. 
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 Sclerostin, encoded by the sost gene, is produced primarily by osteocytes.. (52). 
Mechanical unloading cause’s up-regulation of sclerostin, a potent inhibitor of bone 
formation and growth. It competitively inhibits the Wnt/ȕ-catenin signaling in 
osteoblasts which is primarily responsible for bone formation. Sclerostin causes up-
regulation of RANK Ligand and down-regulates OPG (Osteoprotegrin) expression by 
osteocytes, which increases osteoclast differentiation and activity, leading to bone 
resorption. 
  
Sclerostin and Dickkopf-related protein 1 (Dkk1), inhibit the Wnt pathway by 
preventing the formation of the Wnt-Frizzled-LRP5 complex by promoting the 
internalization of the LRP5/6 coreceptor or by competitive binding to LRP5.(53) 
  
PTH levels are suppressed following acute SCI probably due to the hypercalcemia that 
accompanies increased bone loss as. PTH inhibits sclerostin production where as 
intermittent PTH treatment has been proved to stimulate bone formation in humans. 
Thus if PTH act as negative feedback regulator of sclerostin, suppressed PTH in acute 
SCI would exacerbate sclerostin-mediated bone loss. However, these complex 
associations remain unsolved in acute SCI and needs further research.  
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BONE LOSS IN SCI  
In comparison to bone loss of other immobilizations (TBI, CVA) bone loss in spinal 
cord injury is rapid and severe which suggest additional aetiologies contributing  to  
reduced bone strength(55). Identification of pathway related to mechanical loading 
has significantly improved our understanding regarding the loading mechanism and its 
regulation by mechanosensor osteocytes. Still the quest for therapeutic agents to 
prevent the bone loss on unloading remains unsolved; hence it becomes essential to 
explore the other causes responsible for bone loss. Neural and endocrinal factors  
affect the process of bone remodeling and hence the bone loss(56). A number of 
hormonal changes takes place following spinal cord injury which may explain the 
excess bone turnover (1). Suppression of PTH-Vitamin D axis following 
hypercalciuria in the acute phase of spinal cord injury may contribute to sclerostin 
induced bone loss. Low vitamin D levels and low sun exposure following injury and 
steroids in the course of treatment. Inhibitory effect of Spinal Cord Injury on the 
synthesis and secretion of sex steroids contributes to the pathogenesis of SCI induced 
osteoporosis (26)(50).  Hypercalcemia following Spinal cord injury suppresses the 
PTH- Vitamin D axis   as a result of which negative calcium balance persists in the 
acute phase.  Recent studies reveal the role of PTH in suppression of sclerostin a 
protein molecule, supposed to be associated with SCI-induced bone loss. Sclerostin, is 
encoded by the sost gene, produced by osteocytes, Sclerostin reduces Wnt/ȕ-catenin 
signaling in osteoblasts and reduced bone formation.(57) 
Spinal cord injury mediated hormonal changes and inadequate Vitamin D levels may 
contribute to rapid bone loss and osteoporosis.(1) Vitamin D deficiency has been 
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reported to have high prevalence in acute spinal cord injury patients and may be a 
factor for rapid bone loss in acute phase of spinal cord injury.(58) 
Studies have shown adequate Vitamin D replacement in spinal cord injury patients  
helps to reduce the bone loss by decrease in bone resorption markers.(59) These 
findings make us explore the equation between vitamin D and rate of bone loss in 
spinal cord injury patients. Remodeling comprises of bone formation and resorption, 
the bone loss in spinal cord injury is explained by the fact that bone formation shows 
minimum rise whereas bone resorption significantly increases(61). Formation and 
resorption biomarkers give some idea about the rapid turnover and therefore throw 
light on the mechanism and quantity of bone loss. This bone loss in later stage 
presents as osteoporosis and predisposes to low trauma fractures such as fall during 
transfers, from wheel chair or from standing height.(58)(62) Bone turnover is rapid 
during the acute phase and thereafter plateaus to continue at slower rate for few 
years.(63) Prevention of bone loss beyond the fracture risk or fracture threshold levels 
can largely avoid the low trauma fractures. In spite of significant literature, suggesting 
early bone loss in spinal cord injury, none quantifies the loss and its progression with 
time. This study observes the bone resorption and formation markers over a period of 
six months and compares with bone markers of pre and post menopausal females from 
the community.     
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OSTEOPOROSIS IN SPINAL CORD INJURY 
Osteoporosis is an inevitable complication found in almost every individual following 
Spinal cord injury. Osteoporosis is often treated only when patient has obvious 
clinical fractures. As the treatment following fracture is quite difficult and non 
satisfactory, there has been paradigm shift towards the approach to problem: 
Prevention of acute bone loss in SCI (<1 year) and effective treatment of established 
low bone mass with long-standing SCI (≥ 1 year).(64) 
Osteoporosis is defined by the World Health Organization as a condition characterized 
by “low bone mass and micro architectural deterioration of bone tissue leading on to 
increase in the bone fragility and predisposing to fracture(65).  Among the various 
modalities currently available to diagnose osteoporosis, assessment of the bone 
mineral density by dual-energy X-ray absorptiometry is most commonly used in 
clinical practice. Despite being the current practice, BMD has several limitations in 
qualifying as an ideal diagnostic test for assessment of osteoporosis. Addition of 
clinical risk factors to the BMD value has led to the development of SCI FRAX-
Spinal Cord Injury Fracture Risk Assessment Tool which helps in predicting the risk 
of fracture development.(66) However, both SCI FRAX and BMD assessment failed 
to incorporate one of the most important factor determining bone strength i.e. bone 
remodeling.(65) Moreover BMD do not give us correct idea about the bone loss when 
repeated within a period of 12 months. This has led to the development and use of 
bone turn over markers (BTM) which guides us about the bone loss over a period of 
time. Recent literature reports about 30%  bone loss within one year of injury, hence it 
becomes essential to observe the change over a period of time, and prevent the bone 
63 
 
loss earliest possible.(67)  Hence the bone markers are very important in identification 
of the peak phase of bone loss, which is difficult to detect with the DEXA scan. 
The most commonly used bone resorption marker is breakdown products of type 1 
collagen (amino or carboxy terminal cross linking telopeptides, pyridinium cross 
links). This study will enable us to study the rate and pattern of bone loss in patients 
with acute spinal cord injury in comparison with age matched healthy controls (pre 
and postmenopausal females). This would help to take appropriate measures to 
prevent bone loss, osteoporosis and low trauma fractures during the chronic phase. 
 
Magnitude of osteoporosis in the Indian SCI population 
Bone loss is an inevitable complication of spinal cord injury. It is reported to be found 
in almost every individual at certain point of time following spinal cord injury. Hence 
primary prevention of the disease becomes essential both for the patient and the health 
care givers. The prevalence of osteoporosis is about 80% in spinal cord injury 
patients.  A wide range of facture prevalence (1-35%) has been reported and it 
increases with increase in age.(3)  After an initial phase of rapid bone loss, the bone 
remodeling rate plateaus down but do not touch the baseline and continue at the same 
rate thereafter.(68)(56) Immobilization, reduced sun exposure, inadequate nutritional 
status, hormonal imbalance all these risk factors put the spinal cord injury patients at 
high risk for osteoporosis.  Hence it becomes essential to evaluate the bone loss in the 
acute phase and prevent the rapid bone loss, which ultimately will prevent 
osteoporosis.(69) No Indian literature is available correlating the biomarkers and bone 
loss in spinal cord injury patients. 
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BONE METABOLISM MARKERS 
These are the newer modalities of assessment of dynamic activity of bone. They 
provide us information regarding the different phase of activity and are broadly 
classified as formation and resorption markers.   
 
Marker of bone resorption  
C Telopeptides (CTX) 
The bone resorption markers are breakdown products of type 1 collagen. 
They are derived from the carboxy terminus of the type 1 collagen as result of 
oosteoclastic activity. This can be measured both in the serum and urine. The C 
terminal telopeptide of type 1 collagen undergoes beta isomerization and 
racemization, which is an age dependent process and hence the ratio of alpha to beta 
CTX can differentiate recently broken down collagen to aged collagen and used as an 
index of rapid bone turnover. This ratio is more in patients with high bone turnover 
like Pagets disease and reduces with bisphosphonate therapy.  These  are not only 
useful in assessing the need for treatment and response to treatment, if these levels are 
higher in post menopausal women they would predict a higher risk of fracture(70). 
 
Measuring ranges 
Male 20-50 years – Normal range 142-584 pg/mL  
Female premenopausal - Normal range 137-573 pg/mL 
Female postmenopausal - Normal range 226-1008 pg/mL 
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The detection limit represents the lowest measurable analytic level other than zero.  It 
is calculated as two standard deviations above the lowest standard (standard 1 + 2 SD) 
repeatability study. 
Analytical sensitivity:  Lower limits of measurement 
Analytical specificity:  No cross reactivity was detected with monoclonal antibodies 
for beta cross laps, parathyroid hormone and bone specific alkaline phosphatase. 
 
Markers of Bone Formation   
Bone formation markers are by products of osteoblasts expressed at different phases 
of osteoblast activity hence they reflect different osteoblast function and of bone 
formation.  
Serum Total Alkaline Phosphatase (AP) 
Alkaline Phosphatase is anchored to the cell surfaces of osteoblasts. The precise 
function of AP although not clearly known, it is supposed to play a role in osteoid 
formation and mineralization, by degradation of the mineralisation inhibitor 
pyrophosphate.(71).The advantages being its low intra-individual variability (<10%), 
minimal effect on renal function, minimal interaction with food, long half-life (1–2 
days), sample stability and cheap rates. (72)(73)  It has about 20% cross reactivity 
with liver isoforms. In adults with normal liver function, approximately 50% of the 
total Alkaline Phosphatase activity is derived from the liver, whereas 50% arises from 
bone. If hepatic dysfunction is ruled out, serum levels of total AP gives good 
impression regarding new bone formation and osteoblast activity.  Variation with 
exercises is minimal, i.e. less than 25% of LSC. (least significant change).(74).From a 
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clinical perspective, detection of the bone-specific AP (BAP) isoenzyme is preferred 
because of higher specificity.(75) 
Osteocalcin (OC) 
Osteocalcin is a hydroxyapatite-binding protein synthesized by osteoblast and 
hypertrophic chondrocytes.  It is also called as the bone gla protein and constitutes 
15% of the non collagenous bone matrix. OC is an active molecule involved in the 
organization of the extracellular matrix. Previous studies suggest OC involvement in 
osteoid mineralisation, as it is expressed mainly during bone formation. OC is 
considered a specific marker of osteoblast.(76) Intact molecule of osteocalcin is 
unstable, having a short half-life of a few minutes. OC gene is regulated at 
transcriptional level by Vitamin K and 1,25-OH2 Vitamin D, which act cofactors for 
Ȗ-carboxylation of OC resulting in increased affinity for calcium and 
hydroxyapatite(77). It has short half life, large inter-lab variation and is influenced by 
Vitamin K status, renal function and circadian rhythm.(78) 
            
Measuring ranges 
Male < 30 years – Normal range 24-70 ng/mL  
Male 30-50 years- Normal range 14- 42ng/mL 
Female premenopausal - Normal range 11-43 ng/mL 
Female postmenopausal - Normal range 15-46 ng/mL 
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Relevance of measuring bone markers in acute spinal cord injury scenario 
Bone markers can be tested early in the course of treatment (as early as 3 
months).This will enable the treating physician to keep track on the dynamic changes 
in the bone, which is not significant with DEXA scan, check compliance and adequate 
response to therapy even before second DXA scan showing improvement in Bone 
Mineral Density. It is not an expensive (INR 200) investigation. If measurements fail 
to show an improvement, alternative medications or parenteral therapy (if patient was 
already on oral medications, ex: Bisphosphonates can be used for treatment. 
The role of repeat BMD is not yet proven to correlate with anti fracture effects or 
reduction in fracture risks, rather some other non clinical parameters are thought to be 
better predictors of fracture risks.(22) (23) Increased bone loss and osteoporosis are 
inevitable complications of spinal cord   injury.(1,58,68,79,80) Reduced bone strength 
predisposes them to low-trauma fractures.(58,66,81)(3) Fracture  affects the freedom 
of mobility, activities of daily living and quality of life of persons and increases the 
duration and cost of hospitalisation with spinal cord injury.(63) Pitfalls - No ethnicity 
specific values. No studies in Indian population  has been done to assess the rate of 
bone loss in  acute spinal cord injury patients, especially in the acute phase where 
literature worldwide are also few.(82) Prevention of bone loss beyond the fracture risk 
or fracture threshold levels can largely avoid the low trauma fractures.(66) This can be 
done by routine assessment of risk factors and secondary causes of osteoporosis 
among spinal cord injury patients. Currently there is no evidence to suggest Vitamin D 
levels correction to therapeutic levels may prevent bone loss (81),(83), but there are 
promising results with antiresorptive agents which  may prevent osteoporosis and low 
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trauma fractures.(77)(78) This study will enable us to compare bone loss in spinal 
cord injury patients with the control/ high risk groups; pre and post menopausal 
females. This will help to identify early bone loss and emphasize on early treatment in 
acute phase to prevent osteoporosis and low trauma fractures in chronic spinal cord 
injury patients.  
 
Bone markers in the assessment of fracture risk 
 After long duration research and clinical trials, Bone Turn over Markers (BTM) are 
now recognised as tools for clinical management of metabolic bone diseases. Some of 
the markers lack clinical correlation and are limited by the high biological and 
individual variability; few like C Telopeptide represent more realistic applications of 
bone markers in clinical studies. Large epidemiologic studies have shown that bone 
remodeling and its products the bone turnover markers are independent contributors of 
fracture risk and are correlate well with therapeutic management.(86) 
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VARIABILITY OF BONE MARKERS IN DIFFERENT INDIVIDUALS  
 
Intra subject variability poses a major difficulty in practical use of bone bio markers. 
Whenever a change is observed in bone marker levels, in an individual patient (e.g. 
following an intervention), this must be interpreted against the background of possible 
variability associated with the particular marker. Therefore, knowledge regarding 
sources of variability and different strategies to cope with them are essential for the 
meaningful interpretation of results. 
A number of factors need to be considered when serial measurements of biochemical 
markers are assessed to determine changes in bone turnover. To minimize limitations 
linked with analytical variability, standardized sampling and sample handling methods 
are mandatory for obtaining reliable results. 
In addition to parameters of assay performance factors such as the choice of sample 
(i.e. serum versus urine), correct handling, processing and storage of specimens 
should be considered. All these steps are important as the technical sources of 
variability are controllable and modifiable. Some bone markers are temperature 
sensitive, some are sensitive to haemolysed sample which result in values that are 
either too high or too low. Osteocalcin is usually more sensitive, but variations have 
been described in other serum markers also. 
Intra-individual (i.e. biological) variability is difficult to control than the technical 
aspects of variability. Age, gender, ethnicity are the non modifiable biological 
variations. All these factors should be considered while interpreting the results of bone 
bio markers. Serum and urinary concentrations of bone markers are high during 
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normal puberty and growth phase, but declines as the growth subsides. These are 
usually stabilised by the 3rd decade in healthy men, and practically remain more or 
less unchanged until 70 years. Spinal cord injury is associated with a substantial 
increase in bone turnover, evidenced by a 50–70% increase in bone resorption 
markers. Some biomarkers of bone are excreted via kidney (i.e. OC, C Telopeptide), 
change in glomerular filtration may significantly affect urinary and serum 
concentrations. Hence serum creatinine levels are monitored to look at the variations.  
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MATERIAL AND METHODS 
This is a prospective study of bone biomarkers in patients with acute SCI enrolled 
within 1 months of sustaining injury.  This study was conducted in the Department of 
Physical Medicine and Rehabilitation. Acute spinal cord injury patients aged between 
18-45 years, who met the inclusion and exclusion criteria were enrolled for a period of 
6 months from April 2014 to June 2015.  Thirty patients were enrolled for the study; 
twenty acute spinal cord injury patients completed the study. Baseline demographic 
parameters, age, sex were assessed. Serum calcium, phosphorus, creatinine, albumin 
and alkaline phosphatase were assessed as part of routine clinical evaluation. Fasting 
samples of Serum C Telopeptide and Osteocalcin, bone resorption and formation 
markers respectively were collected. Patients with hyperthyroidism, 
hyperparathyroidism, hepatic or renal dysfunction, malabsorption or on medications 
for osteoporosis were excluded. Enrolled patients were followed up with serial 
estimation of bone biomarkers at 1, 3 and 6 months. Data was collected to observe the 
change in bone biomarker levels among acute SCI patients over a period of six months 
and statistically analysed. In addition, serum bone biomarkers of the patients were 
compared with age matched individuals from the community, from another study 
conducted at Endocrinology Department of our institution. 
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DIAGRAMMATIC ALGORITHM OF THE STUDY  
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PARTICIPANTS 
 
Inclusion Criteria:  
 Patients < 1 months of traumatic spinal cord injury 
 Age group 18 -45 years. 
 
 
 Exclusion Criteria:  
 Patients with non traumatic spinal cord injury. 
 Patients with renal failure (Contracted kidneys in the ultrasound and serum 
creatinine >1.5 mg% ) 
 Patient with bone disease (Including Heterotopic Ossification )        
 Patient already on other treatment for osteoporosis. 
 Patient taking drugs regularly for other diseases, which are likely to develop 
osteoporosis (e.g. steroids, anti-inflammatory agents etc.)  
 Patient who is not able to give informed consent. 
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STATISTICAL METHODS 
All baseline variables were expressed in terms of mean ± SD, if they are continuous 
variables. All categorical variables were reported using frequencies and percentages. 
The distribution of CTX and Osteocalcin was checked by plotting the histogram and 
QQ plot. If the distributional assumption satisfies normality, then the measurements 
will be expressed as mean and standard deviations. If not normally distributed, 
Shapiro Wilk’s test was performed to check for normality assumption and then 
median with inter quartile range was reported. The comparison of the two groups was 
done using t-test for the change in bone markers at 1st and 3rd and 3rd and 6th month of 
SCI, if assumption of normality held good. If not, Mann Whitney U test will be done 
to compare between the groups. Bonferroni correction was used to adjust the p value. 
ANOVA was used to compare more than two groups. All the analysis was done using 
SPSS (version 16). 
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RESULTS 
During six-month study period, 30 subjects were enrolled among which 20 completed 
the study. Two patients refused to participate, one was detected to have Heterotopic 
ossification (HO) and seven patients were lost to follow after discharge. Most of the 
patients were from remote areas and were unable to continue participation. There were 
19 males and 1 female in the study. Mean age at the time of SCI was 29.3 years (18–
45 yr). Among the 30 patients enrolled, two refused consent, one had Heterotopic 
ossification (HO) and seven were lost to follow up after discharge. Two had lower 
limb deep venous thrombosis and Heterotopic Ossification (HO) both simultaneously. 
Among two patients with HO, in one patient it was detected at 4 month duration, and 
was not included in the study. One patient lost to follow up after 3rd month later 
presented with HO. 
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The severity of the injury was assessed by ASIA score (American Spinal Injury 
Association Score: Classified from A to E) A indicates the maximum severity and  
poor prognostication and E indicates the best prognosis similar to normal. In this 
study patient with ASIA A-C has been included as they are most likely to be affected 
with spinal cord injury related bone loss. 80% (n=15) of the population was ASIA-A, 
5 % (n=1) ASIA-B, and 15 % (n=3) ASIA-C. Patients with ASIA-A had highly  raised 
bone resorption marker C Telopeptide, in comparison to ASIA –B and ASIA- C. but 
was statistically not significant (p value - 0.069) where as no correlation was observed 
with bone formation marker Osteocalcin. As patients with ASIA-B and ASIA-C were 
few it was difficult to comment on its statistical association with the bone markers. 
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Biochemical data 
Serum calcium levels were within normal range (8.3-10.4 mg/dl) at one month of the 
study. PTH levels were at the lower normal range (8-74 pg/ml) with the mean value 
being 15. 2pg /ml (shown in Figure 3 below) this can be probably explained by the 
fact that immobilisation related hypercalciuria causes suppression of serum PTH and 
1, 25 (OH) Vitamin D axis. 
    
The mean vitamin D level among study population was 14.9 IU (Normal 20-30 IU). 
This can be probably due to poor nutritional intake, inadequate sunlight exposure or as 
a response to hypercalcemic status during early phase of injury. It was observed that 
there was no correlation between serum vitamin D levels and bone biomarkers namely 
C Telopeptide and Osteocalcin (Figure 4a and 4b). Bone-specific alkaline phosphatase 
constitutes 50% of total AP, and in absence of liver disease, it reasonably reflects bone 
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formation in our subjects. Total Alkaline phosphatase (tAP) was marginally raised at 
one month of study and not significantly greater than those at baseline.  
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Bone formation marker, Serum Osteocalcin levels were assessed at 1, 3, 6 month. It 
was observed that there was a marginal rise at the 3rd and 6th month.  Serum 
Osteocalcin levels of these patients were compared with Osteocalcin levels of pre and 
post menopausal females from the community. It was noticed that there was modest 
rise in Osteocalcin levels among SCI patients, but was statistically insignificant in 
comparison to post menopausal females. (Figure 5, 6) Osteocalcin levels were 
measured from morning fasting blood sample. The upper normal range of 
premenopausal women as taken from our reference laboratory values was 30ng/dl. In 
this study pre menopausal females represented the normal population and the post 
menopausal women represented the group vulnerable to osteoporosis.  
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Bone resorption marker, Serum C telopeptide levels were assessed at 1, 3, 6 month. It 
was observed that there was significant rise in bone resorption markers in comparison 
to normal C telopeptide levels. Maximum rise was observed at 3 to 4 month interval 
following which there was a statistically significant drop at 6 month, but the CTX 
levels were still persisted significantly higher than the base line values, suggesting 
ongoing bone loss. Serum C Telopeptide levels of these patients were about 3 times 
increased in comparison to the mean values of C telopeptide levels of Pre and post 
menopausal females.(Figure 7 and 8) In this study pre menopausal females 
represented the control group and the post menopausal women represented the group 
vulnerable to osteoporosis. 
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Mean values of serum Osteocalcin and Ctelopeptide were compared among patients 
with flaccid paralegia and patients with spastic paraplegia.There was no significant 
corelation between tone of the muscles (spasticity or flaccid) and bone markers as 
shown in figure 9 below. 
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86 
 
DISCUSSION 
This is a longitudinal study observing the bone activity among acute SCI patients by 
means of bone markers. These bone turn over markers show ongoing metabolic 
changes during the period of study. Acute SCI causes significant 
neuromechanochemical changes in the body, as a result of which sublesional skeletal 
system undergo rapid remodelling, i.e. increased rate of bone resorption and bone 
formation. In this study the most striking feature noticed was the bone resorption 
activity (indicated by serum C Telopeptide levels), was about 3 times higher than its 
upper normal limit. In contrast, there was a modest rise in bone formation marker, 
Osteocalcin and tAP, marginally raised than the reference values. This indicates gross 
uncoupling of remodelling cycle in favour of bone resorption, where bone formation 
lags behind significantly.  
 
Significant rise in resorption markers were observed at 4 weeks of SCI. Highest values 
were noticed around 12–16 weeks, followed by a statistically significant (p value - 
0.008) dip at 24th week. Although there was a significant drop observed at sixth 
month, the resorption markers remained significantly higher than normal base line 
values. Literature suggest raised bone markers due to increased bone turnover activity 
after acute SCI, which return towards baseline by 6–14 months, maximum bone loss 
being at 4 months post injury.(2)(87) In this study bone markers value have not 
reached the baseline at 6 month interval, suggesting ongoing resorption activity and 
bone loss. As revealed from a study, 30% of the post menopausal females lose bone at 
faster rate than the normal; similarly each spinal cord injury patient may behave 
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differently according to their level and grade of injury.(71) Thus serial monitoring of 
bone markers helps to appropriately judge the bone activity.  
 
Bone markers of premenopausal and post menopausal females were taken from 
another study (Conducted by the Department of Endocrinology) at our institute as 
control values. Premenopausal females were taken as base line controls and 
postmenopausal females were taken as vulnerable group to bone loss and 
osteoporosis. Bone markers of both these group were compared with mean values of 
bone marker in acute SCI patients. As observed in this study, bone resorption marker, 
C Telopeptide levels were significantly higher than post menopausal females. This 
suggests that multiple factors other than hormonal imbalance are responsible for acute 
bone loss. Prolonged lack of a loading response during the acute stage probably down 
regulates the mechanosensory feed back at the cellular level (Osteocytes), which is 
responsible for promoting bone formation and  inhibiting the resorption promoting 
agents like sclerostin. Normal muscle tone is under the influence of CNS (Brain and 
spinal cord) and is regulated by feedback mechanism from the stretch reflex. 
Specialised sensory organs, muscle spindles act as receptors to “stretch” and carry 
afferent impulses via dorsal root to spinal cord, where it activates the alpha motor 
neuron to cause contraction of extrafusal muscle fibres. Hence, stretch increases 
afferent firing and activates motor neurons to contract the muscle and reduce afferent 
firing. Acute SCI presents with a state of spinal shock, resulting in flaccid muscle tone 
due to neuronal disruptions within the cord. Flaccid muscle tone may further minimise 
the mechanosensation, in addition to mechanical unloading, at the cellular level and 
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aggravate the bone loss by rapid recruitment of resorption activators which results in 
early and significant bone loss. However in this study comparison of bone markers 
among patients with spastic and flaccid muscle tone after SCI did not show any 
significant correlation. Further studies comparing bone markers with spasticity in 
large number of patients may provide better insight regarding the association of bone 
markers with muscle tone. 
 
 At 4 weeks, the cohort had calcium values within normal range (8.5-10.5 mg/dl.  ). 
An interesting observation was of serum PTH levels, which were at the lower normal 
range (Normal 8-80 ng/dl) in most of the SCI patients.  The mean value of serum PTH 
level among these patients was 15.2ng/dl. Only four patients had PTH values > 20 
ng/dl, among which one patient had Heterotopic Ossification (HO), two were of ASIA 
B and two of ASIA C, none with ASIA A. The dynamics of PTH with neurological 
severity, bone resorption and HO needs to be further evaluated with serial PTH 
monitoring. In this study no correlation was observed between PTH and bone markers. 
Lower distribution of PTH levels may probably be due to mobilization of skeletal 
calcium because of SCI related immobilisation hypercalciuria. Studies have shown 
that PTH remain suppressed for about 1–4 months post-SCI and then return towards 
normal range.(88) None of the subjects in the study developed clinically significant 
hypercalcemia. 
 
Most of the study patients (n=16) had Vitamin D levels < 20 IU and were started on 
supplementation with oral cholecalciferol. No association was observed between 
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Vitamin D and bone markers, suspecting its role in acute bone loss. Moreover, reliable 
dietary details were not obtained hence it was difficult to comment on its effect on 
bone biomarkers. Inpatients in rehabilitation centre spend time outdoors with adequate 
sunlight exposure which will help to prevent hypovitaminosis D. As secretion of 
Osteocalcin is dependent on Vitamin D, supplementation of vitamin D may have 
influenced Osteocalcin results.(89)(90) Statistically no correlation was observed 
between Vitamin D and serum bone biomarkers. 
 
Bone densitometry was not a part of this study as change in DEXA scan becomes 
noticeable only after 6-12 months of duration usually in the lower limbs. BMD is 
preserved at the lumbar spine in SCI patients, probably due to loading of vertebral 
column on attaining the sitting posture whereas distal femur BMD is depleted by 22% 
at 3 months, 27% at 4 months, and 32% at 14 months.(87) BMD of entire lower limbs, 
instead of a part of lower limb decreases the error as larger area is being measured. 
Review from previous studies show significant difference in BMD at the lower end of 
femur and proximal tibia as the earliest one to involved with maximum change 
noticeable in this region.(2) BMD of the lower limbs probably at one or two year 
interval until the biomarkers reach the baseline (state of normal bone turn over 
activity); may be a good option for knowing the residual density at that point of time. 
Bone biomarkers reflect the bone activity, it does not comment on the bone mineral 
density (BMD) as standardised by Z- Score of - 2.5 and -1.5 for osteoporosis and 
Osteopenia respectively. Z scores at the baseline remodelling rates will indicate no 
further risk of active bone loss, where as Z scores with increased resorption rates will 
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indicate higher risk for fracture. Hence both together can prognosticate the fracture 
risk better than being guided by individual parameters.   
 
Source of potential bias was the varying degrees of mobilisation (wheel chair/ Crutch 
ambulation) and duration of mechanical loading depending up on their neurological 
levels. All the participants continued the routine therapy during their stay in 
rehabilitation centre, which included wheel chair ambulation, therapeutic standing and 
ambulation with walker and elbow crutches, as per there neurological levels. To avoid 
heterogeneity of the population, SCI patients with quadriplegia were not included in 
the study.  
 
Sublesional fractures are more common in paraplegics than in quadriplegia 
population. This may be due to increased independence in mobility in paraplegics 
which makes them prone to trivial trauma, while ambulation or transfers. 
Prospectively looking at spinal cord injury population, admitted during the year 2014-
2015 revealed 17 SCI patients having lower limb fractures. Most of them are 
paraplegics performing transfers and ambulation independently. The history of 
fractures almost never pointed towards an event / trauma pertaining towards fracture. 
This suggests trivial trauma at the back ground of sublesional fractures. Long term 
prospective studies including larger numbers of subjects, with appropriate 
stratification OF neurological level of impairment (ASIA Grading), degree of 
immobility and presence or absence of spasticity will provide further insight in the 
mechanism of fractures. Recent prospective longitudinal study showed 25 % of 
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traumatic SCI had fractures. None of the factors correlated with fractures, except 
ASIA grading. ASIA A SCI patients had highest risk of fractures and were mostly 
observed after 6 years of injury.(8) In this study, analysis of ASIA A scores and bone 
biomarkers suggested that there was correlation between ASIA A and resorption 
markers, where as there was no correlation with bone formation markers. As there 
were only 5 patients with ASIA B and C statistical correlation was insignificant. This 
may be due to extensive paralysis seen in ASIA - A group of patients.  
 
 
This was a longitudinal study of bone markers among acute SCI patients to detect 
early bone changes in patients following acute SCI. It showed significant rise, (about 
3 times of upper normal limit) in bone resorption marker, C Telopeptide, suggesting 
ongoing rapid bone loss. Based on the results of this study, it would be interesting to 
notice the response of the biochemical markers when treated during the acute phase of 
SCI. It also would help to select appropriate medications which would prevent bone 
resorption or facilitate osteogenesis.  
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LIMITATIONS 
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LIMITATIONS 
 
1. Although the results of bone resorption markers was concrete, other parameters and 
its correlation with the severity of injury (ASIA scale) was not clearly established due 
to small sample size..  
2. It was a 6 month follow-up study, at which the bone markers did not reach the base 
line levels. A long term study (2 year follow up), combined with bone markers and 
Dexa Scan (one year interval) will probably provide better insight regarding dynamic 
bone activity and available density at a particular time interval. 
 
3. Stratification of patients according to their neurological level and ASIA grading, 
tone of the lower limbs (spasticity / flaccidity), mechanical loading and  participation 
in mobilisation activity varied in all the subjects according to their neurological status 
and their level of activity. 
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CONCLUSIONS  
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CONCLUSIONS  
 
1. Biochemical markers of bone turnover observed longitudinally in a cohort of 
acute SCI patients demonstrated a dramatic rise in bone resorption markers but 
only a modest rise in bone formation markers. 
  
2. When compared to age matched premenopausal females, taken as control 
group and post menopausal females as vulnerable group there was significant 
rise in bone resorption markers.  
 
 
3. Bone markers show significant changes as early as one month after SCI, much 
before DEXA Scan detects Osteopenia and Osteoporosis. The resorption 
markers started declining after 4 months of SCI but did not return to base line 
until 6 months suggesting ongoing bone loss at significantly higher levels.  
 
4. It was observed that there was no correlation between serum vitamin D levels 
and bone biomarkers  
.  
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FURTHER RESEARCH RECOMMENDATIONS 
 
 Fracture prevention should be the goal in people with SCI as it increases the 
morbidity significantly. Hence would suggest longitudinal studies of bone biomarkers 
until these returns to base line and its relation with BMD of lower limbs. This would 
help to initiate appropriate treatment sufficiently early to prevent pathological 
fractures among SCI patients. Further studies to observe the response of bone 
biomarkers on treatment with different pharmacological agents that influence bone 
remodeling will be the next step ahead in minimising early bone loss and preventing 
pathological fractures. 
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PATIENT INFORMATION SHEET: 
You are being requested to participate in the study. A study, regarding the strength of 
the bone following spinal cord injury.3 samples of blood will be collected and the 
samples will be analyzed after 1 year.  A correlation between study results and the 
bone strength or bone loss will be made.  
1. WHAT IS THE PURPOSE OF BLOOD COLLECTION? 
In this study, three samples of blood (5 ml each time) at 1, 3, and 6 month interval 
following spinal cord injury will be collected. The blood sample will be analyzed for 
routine investigations and bone biomarkers for the first sample and second and third 
one for bone biomarkers only. 
These blood test results will help the patient to know their routine blood parameters 
after spinal cord injury. Moreover the study of biomarkers over six months will give 
some information regarding the bone changes.  
2.  WHO WILL COLLECT THE BLOOD?   WHAT ARE THE POSSIBLE 
COMPLICATIONS? 
Blood sample will be collected by trained staffs only. The blood taking procedure 
will be sterile and done with all aseptic measures. The complications that can 
occur with blood collection are pain, swelling and hematoma. The pain is the most 
common and usually resolves within minutes. There are least chances of other 
complications .Even if they do occur they will be treated for it in the hospital. 
3. WILL WITHDRAWL OR NON PARTICIPATION AFFECT THE USUAL 
TREATMENT? 
The patient can withdraw from the study at any point of time and is also free to decide 
regarding his participation. Non-participation or withdrawal will not affect your usual 
treatment at any point of time during the hospital stay. 
4. DOES THE PATIENT HAVE TO PAY FOR THE INVESTIGATIONS? 
The patient included in the study will not have to pay for any of the additional blood 
investigations done for study purpose. 
5. WILL MY BLOOD REPOTS BE KEPT CONFIDENTIAL? 
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The results of the study will be published in a medical journal but you will not be 
identified by any name in any public presentation of results. However your 
medical notes may be reviewed by people associated with the study, without any 
additional permission, should you decide to participate in the study. 
For any further questions, contact: Dr. Prince Thakkar- 09843766039, 
Department of Physical Medicine and Rehabilitation, 
 PMR -0416 2282158, 0416 5212158 
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Informed Consent form 
 
1. Study Title:  To observe the rate of bone loss in acute spinal cord injury patient’s by means of 
bone biomarkers.  
Study Number: 
 
Subject’s Initials: _________ Subject’s Name: ________ 
 
Date of Birth / Age:_______ 
 
Please initial box  
 
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ 
for the above study and have had the opportunity to ask questions. [  ] 
 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 
(iii) I understand that the Sponsor of the project, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published. [  ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v) I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/ 
Legally Acceptable Representative:___________________________________ 
 
Date: _____/_____/______Signatory’s Name: _________________________________ 
 
Signature/thumb of the Investigator: _________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: Dr. Prince Thakkar (Ph no. 09843766039, 0416-2282158) 
Signature of the Witness (or Thumb impression): __________Date: __/_____/_______ 
 
Name of the Witness: __________________ 
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DATA SHEET ( 20 PATIENTS ) 
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SOP’s for Automated Chemistry analysers  
 
BETA CROSS LAPS 
 
            Method to measure C-terminal telopeptide of type 1 collagen(β- cross laps, 
 
           ASSAY METHOD – SANDWICH IMMUNOASSAY 
 
      Immunoassay for  the in vitro quantitative determination of degradation products of type 1 
collagen in human serum. 
The  Elecsysβ-CrossLaps/ serum assay is specific for crosslinked isomerized type 1 collagen 
fragments, independent of the nature of the crosslink (e.g.pyrrole, pyridinolinesetc) 
                The assay specificity is guaranteed through the use of two monoclonal antibodies  
each  recognizing linear β-8AA octapeptides (EKAHD-β-GGR).  
 
             Test Principle 
 
             Sandwich principle.  Total duration of assay: 18 minutes.  
 
 1st incubation: 50µL of sample and a biotinylated monoclonal anti-β-CrossLaps antibody are 
incubated together; the antigen in the sample is liberated from the serum components.  
 2nd incubation: Following addition of streptavidin-coated microparticles and a monoclonal β-
CrossLaps-specific antibody labeled with a ruthenium complex, a sandwich complex is 
formed which becomes bound to the solid phase via interaction of biotin and streptavidin.  
 The reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. Unbound substances are then 
removed with ProCell.  Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier.  
 Results are determined via a calibration curve which is instrument-specifically generated by 
2-point calibration and a master curve provided via the reagent barcode.  
 
 
Limits and ranges: 
 
           Measuring ranges 
0.010-6.00 ng/mL or 10-6000 pg/mL (defined by the lower detection limit and the maximum 
of the master curve).  Values below the detection limit are reported as < 0.010 ng/mL (< 10 
pg/mL). Values above the measuring range are reported as > 6.00 ng/mL (> 6000 pg/mL). 
 
            Lower limits of measurement 
Lower detection limit: 0.01 ng/mL (10 pg/mL).  
The detection limit represents the lowest measurable analyte level that can be distinguished 
from zero.  It is calculated as the value lying two standard deviations above that of the lowest 
standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 20) 
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ALKALINE PHOSPHATASE (ALP) EC 3.1.3.1  
 
Date of introduction: March 1995  
Review Date: annual  
Analyser: Automated Chemistry analysers  
Frequency: daily, Monday to Saturday  
Analysis time: results available the same working day, OP up to 1930 hrs  
Summary and explanation of the test  
Colorimetric, kinetic, p-nitrophenyl phosphate with AMP buffer.  
This is an optimised standard method confirming to the recommendation of the IFCC. The liberated 
phosphate group is transferred to water and the reaction rate is enhanced by certain amino alcohol 
buffers such as AMP ( 2 – amino – 2 methyl-1-propanol ) which act as a phosphate group acceptor.  
Clinical Indications for the test  
Phosphatases catalyse the splitting of phosphate group from monophosphoric esters, those operating 
at a alkaline pH optimum are called ALP. ALP in the serum is a mixture of isoenzymes from liver, 
bone intestine and placenta, occurring particularly in osteoblasts (bone forming cells) and in the 
liver. It is increased in bone disease associated with increased osteoblastic activity and in any form of 
biliary obstruction, which induces enzyme synthesis in hepatocytes adjacent to the biliary canaliculi. 
It is a standard test for bone and liver disorders.  
Specimen type, collection and storage  
Serum is the preferred specimin but lithium heparin plasma is also suitable for this test.  
Stable for 7 days at 40C 0% activity decreased  
7 days at 20-250C 10% activity decreased  
Principle of the method  
The substrate is self indicating as the 4-nitrophenol is converted to 4-nitro phenoxide in alkali with 
increased in absorbance at 415 nm being proportional to the ALP activity.  
ALP  
p-nitrophenol phosphate + H20 ------------> Phosphate + p –nitrophenol  
Source of the Method Protocol  
Tietz NW, Rinker D, Shaw LM. IFCC methods for the measurement of catalytic concentration of 
enzymes 
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N-MID Osteocalcin  
Intended use  
Immunoassay for the in vitro quantitative determination of N-MID osteocalcin in human serum and 
plasma. The determination is used for the control of antiresorptives therapeutic efficiency, e.g. for 
patients with osteoporosis or hypercalcemia.  
The electrochemiluminescence immunoassay “ECLIA” is intended for use on the Roche Elecsys 1010 
and 2010 immunoassay analyzers.  
Summary*1–10  
Osteocalcin, the most important non-collagen protein in bone matrix, is a bone-specific, calcium-
binding protein which is dependent on vitamin K. It contains 49 amino acids and has a molecular 
weight of approx 5800 D. It contains up to three Ö-carboxyglutamic acid residues (bone-GLA-
protein, BGP).  
During bone synthesis osteocalcin is produced by the osteoblasts. Its production is dependent upon 
vitamin K (formation of Ö-carboxyglutamic acid residues) and is stimulated by vitamin D3. After 
release from the osteoblasts, osteocalcin is not only assimilated into the bone matrix but also secreted 
into the blood stream. Accordingly, the serum (or plasma) osteocalcin level is related to the rate of 
bone turnover in various disorders of bone metabolism, e.g. osteoporosis in particular, but also in 
primary and secondary hyperparathyroidism or Paget's disease.  
Osteocalcin is therefore termed a bone turnover marker and is used for this purpose. By means of 
osteocalcin measurements it is possible to monitor therapy with antiresorptive agents 
(bisphosphonates or hormone replacement therapy, HRT) in, for example, patients with osteoporosis 
or hypercalcemia.  
Both intact osteocalcin (amino acids 1–49) and the large N-Mid fragment (amino acids 1–43) occur 
in blood. Intact osteocalcin is unstable due to protease cleavage between amino acids 43 and 44 . The 
N-Mid-fragment resulting from cleavage is considerably more stable.  
The Elecsys N-MID Osteocalcin assay uses two monoclonal antibodies specifically directed against 
epitopes on the N-Mid-fragment and the N-terminal fragment. The test is non-dependent on the 
unstable C-terminal fragment (amino acids 43-49) of the osteocalcin molecule and thus ensures 
constant measurement results under routine conditions in the laboratory.  
**Tris(2,2’-bipyridyl)ruthenium(II) complex (Ru(bpy){)  
Test principle*  
Sandwich principle. Total duration of assay: 18 minutes  
1st incubation: 20 μl of sample, a biotinylated monoclonal N-MID osteo-calcin-specific antibody 
and a monoclonal N-MID osteocalcin- specific antibody labeled with a ruthenium complex** react to 
form a sandwich complex.  
2nd incubation: after the addition of streptavidin-coated microparticles, the complex becomes 
bound to the solid phase via interaction of biotin and streptavidin.  
The reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. Unbound substances are then removed with 
ProCell. Application of a voltage to the electrode then induces chemilumin-escent emission which is 
measured by a photomultiplier.  
Results are determined via a calibration curve which is instrument-specifically generated by 2-
point calibration and a master curve pro-vided via the reagent bar code.  
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Assay*  
For optimal performance of the assay it is important to follow the dir-ections given for the analyzer 
used, and to check that the system’s inventory of assay materials and other consumables is adequate.  
Resuspension of the microparticles before use and the reading in of the test-specific parameters via 
the reagent bar code take place auto-matically. No manual input is necessary. If in exceptional cases 
the bar code cannot be read, enter the 15-digit sequence of numbers.  
Elecsys 2010: Bring the cooled reagents to approx. 20°C and place on the reagent disk of the 
analyzer. Avoid the formation of foam. The system automatically regulates the temperature of the 
reagents and the opening/closing of the bottles.  
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Elecsys 1010: Bring the cooled reagents to approx. 20–25°C and place on the sample/reagent disk of 
the analyzer (ambient temperature 20– 25°C). Avoid the formation of foam. Open bottle caps 
manually before use and close manually after use.  
Calibrators*  
Elecsys N-MID Osteocalcin was calibrated against in-house reference standards: osteocalcin in 
analyte-free human serum matrix.11  
Every N-MID Osteocalcin reagent set has a bar-coded label containing the specific information for 
calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer by 
the use of Elecsys  
N-MID Osteocalcin CalSet. 118  
 
Calculation*  
Elecsys 1010 and 2010 automatically calculate the N-MID osteocalcin concentration of each sample.  
The results are given in ng/ml.  
Limitations – interference*11  
The assay is unaffected by icterus (bilirubin < 65 mg/dl), lipemia (Intralipid < 1500 mg/dl) and biotin 
< 100 ng/ml (criterion: recovery within ± 10% of initial value).  
Hemolysis interferes. Erythrocytes contain proteases which degrade osteocalcin. In patients receiving 
therapy with high biotin doses (> 5 mg/day) no sample should be taken until at least 8 hours after the 
last biotin admin-istration.11  
No influence was observed from rheumatoid factor up to 2200 U/ml. There is no high-dose hook effect 
at N-MID osteocalcin concentrations up to 4200 ng/ml.  
In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay 
was found.  
For diagnostic purposes, the Elecsys N-MID Osteocalcin findings should always be assessed in 
conjunction with the patient’s medical history, clinical examination and other findings. 
 
Measuring range- Measuring range- 0.500–300 ng/ml (defined by the lower detection limit and the 
maximum of the master curve). 
                                                               
 
N-MID osteocalcin  
Women, 
premenopausal  
200  31.2  
Women, 
postmenopausal, no 
HRT  
211  41.3  
Men, ≥ 50 years  162  26.3  
 
